“Secukinumab in Moderate to Severe Hidradenitis Suppurativa: Primary Endpoint Analysis From the SUNSHINE and SUNRISE Phase 3 Trials”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 2, Mar. 2023, p. s129, https://doi.org/10.25251/skin.7.supp.129.